Locations:
Search IconSearch
November 12, 2018/Neurosciences/Research

Disease-Modifying Therapy for MS: Discontinuing After Age 60 Appears Safe

Observational study suggests age may be a better guide than disease stability

18-NEU-5744-MS-Therapy-650×450

Stopping disease-modifying therapy (DMT) in patients with multiple sclerosis (MS) after age 60 may be a good strategy, suggests an observational study out of Cleveland Clinic.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Our research indicates that being 60 or older is an important predictor of success for discontinuing DMT,” says Cleveland Clinic neurologist Le Hua, MD, who presented findings from the study at the 2018 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) Congress in October.

She and colleagues retrospectively analyzed a cohort of 600 patients with MS over the age of 60. Of those, 178 patients stopped DMT after being on it for at least two years. Subjects were patients from MS clinics at three Cleveland Clinic locations — in Florida, Nevada and Ohio — where data on quality-of-life measures are collected routinely at clinic visits. The researchers observed minimal effect on quality-of-life outcomes and MRI indicators of disease progression over a median follow-up of more than 18 months compared with the 422 patients in the cohort who continued DMT.

To stop or not to stop?

The question of whether and when to stop DMT in MS is a controversial one. Because DMTs have been clinically available for a quarter century and are increasingly initiated early in the course of MS, many patients have now experienced decades of DMT management, raising concern about the potential for this immune-modulating strategy to cause harm, such as through increased risk of infections.

“It’s suspected that current DMTs may no longer benefit patients past a certain age, due to dwindling inflammatory activity or to a patient’s having already reached significant disability,” explains Dr. Hua, the Eric and Sheila Samson Chair for Multiple Sclerosis Research at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. “This has led clinicians and patients to consider stopping DMT.”

Advertisement

Second analysis of the same cohort

Prior to the current study, Dr. Hua’s team conducted an initial analysis of the same patient population published earlier this year in Multiple Sclerosis Journal (2018 Mar 1 [Epub ahead of print]). That study found only one clinical relapse among the 178 DMT discontinuers. Only 11 percent of patients restarted DMT; those who did so were more likely to have initially discontinued therapy on their own rather than because of physician guidance.

The current analysis evaluated quality-of-life outcomes (EQ-5D® score, Multiple Sclerosis Performance Scales, Timed 25-Foot Walk, Patient Health Questionnaire-9) and MRI changes (number of T1 gadolinium-enhancing lesions and new T2 lesions) in the study population. No significant differences were found between those who stopped and those who continued DMT except for general health status, as measured by the EQ-5D, which showed discontinuers performing slightly better over time. That difference, Dr. Hua cautions, may not be clinically important.

Principles to guide practice

In the wake of her team’s analyses, Dr. Hua points out several principles germane to decisions around whether and when to consider stopping DMT:

  • DMT’s benefits appear to diminish as inflammation naturally wanes. In the normal, healthy population, the immune system starts becoming less functional around age 60. Observation of MS patients indicates that relapses also tend to diminish after that age, and that subsequent disease progression may not be immune-mediated, as it tends not to be associated with MRI-detectable inflammatory activity. While this current study suggests that therapy directed at the immune system may no longer benefit older patients, prior studies involving patients of all ages indicate that outcomes of DMT discontinuation based on disease stability alone tend to be less successful.
  • DMT is not without risk. The benefits of continuing DMT must be balanced against potential adverse effects, including life-threatening infections, other autoimmune diseases, cancers and infusion reactions. Stopping therapy is in a patient’s best interest if it no longer confers benefits.
  • Various factors may be at play. Although there is no set guidance for discontinuing DMT, conventional wisdom holds that patients may try stopping if they have been stable with mild disability for several years — or, alternatively, if they have severe progressive disability despite using DMT. But sometimes the motivating factor is cost, especially if insurance coverage ends or changes. Whatever the reason for stopping therapy, these new analyses provide evidence that it’s likely to be safe to do so in patients over age 60.

Advertisement

Randomized trials needed — and guidance in the meantime

Dr. Hua emphasizes that prospective randomized trials are needed to develop optimal strategies for discontinuing DMT. Cleveland Clinic is participating in one such trial, which is recruiting patients and anticipated to run until 2021. To qualify, patients must be at least 55 years old; have confirmed relapsing-remitting MS, secondary progressive MS or primary progressive MS; and have been using a DMT for at least two years without an MS relapse in the past five years. More details of the trial can be found here.

“We don’t yet have definitive answers for whether and when to stop DMT, but we need to manage patients today based on the best evidence,” adds Dr. Hua. “Our studies provide some reassurance for doctors and patients that discontinuing DMT likely can be done after age 60 without causing harm.”

Advertisement

Related Articles

Illustration of a brain
November 6, 2024/Neurosciences/Research
Genomic Analysis Finds Connections Between Transposable Elements and Alzheimer's Disease

Understanding TE involvement is a key to developing new treatments

Man on an exercise bicycle
October 29, 2024/Neurosciences/Research
New Parkinson’s Trial Focuses on Interplay Between Exercise and Genetics

Study aims to inform an enhanced approach to exercise as medicine

researcher in dark laboratory
September 12, 2024/Neurosciences/Research
Preclinical Imaging Research Aims to Help Refine Deep Brain Stimulation for Stroke Recovery

$3.2 million grant will fund use of calcium-based imaging to record neuronal activity in ischemia model

neurons, axons and synapses in the brain
September 5, 2024/Neurosciences/Research
A Case Study in Neurotherapeutic Clinical Trial Design and Conduct

New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities

Illustration of brain activity
August 28, 2024/Neurosciences/Research
Brain Research Finds Notable Differences in Changes Based on Sex and Race

Chronic stress, asymptomatic disease affect different brains differently

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

22-NEU-2959102-CQD-Hero-650×450
June 15, 2022/Neurosciences/Research
MINDS Study Will Assess Lifestyle Interventions for Slowing Brain Pathology in Preclinical Stages

New grant-funded investigation illustrates impact and reach of Cleveland Clinic Brain Study

22-NEU-2671014-CQD-650×450-Type
March 9, 2022/Neurosciences/Research
A Closer Look at the Cleveland Clinic Brain Study

How the new longitudinal investigation could become the Framingham Heart Study of brain health

Ad